Skip to main content
SP5007,691.76-0.69%DOW53,343.40-0.22%NASDAQ26,289.71-1.33%BTC$64,334.00+0.32%ETH$1,916.31+1.09%GOLD$4,422.90+0.05%OIL$84.97+1.08%
Smart Investors Daily
Sign InSign Up Free
XC

NASDAQ · XCUR

Exicure, Inc.

Healthcare · Biotechnology

$1.43

Up+$0.05 (+3.62%)

Updated Aug 19, 2026, 10:37 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
39.07M
P/E ratio
-4.91
Dividend yield
0.00%
52-week range
$1.18 – $9.48
Volume
28.47K
Avg. volume
653.33K

Price performance

XCUR price history

1M range · 21 trading sessions · Daily adjusted prices

XCUR closed at $1.43 after 21 trading sessions, down 25.91% for the selected period.

Last close
$1.43
Period change
-25.91%
Period low
$1.25
Period high
$1.93
Daily close
View OHLC price history
XCUR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 18, 2026$1.35$1.48$1.35$1.4328.47K
Aug 17, 2026$1.26$1.42$1.26$1.3852.24K
Aug 14, 2026$1.33$1.33$1.25$1.2521.94K
Aug 13, 2026$1.31$1.35$1.18$1.3154.29K
Aug 12, 2026$1.40$1.40$1.30$1.3017.65K
Aug 11, 2026$1.36$1.4399$1.33$1.4037.23K
Aug 10, 2026$1.33$1.43$1.285$1.3760.02K
Aug 7, 2026$1.35$1.43$1.269$1.34539.99K
Aug 6, 2026$1.46$1.46$1.30$1.3556.5K
Aug 5, 2026$1.50$1.55$1.42$1.5128.56K
Aug 4, 2026$1.61$1.63$1.5106$1.5470.53K
Aug 3, 2026$1.52$1.64$1.50$1.5852.22K
Jul 31, 2026$1.65$1.65$1.55$1.6017.7K
Jul 30, 2026$1.74$1.74$1.57$1.5764.14K
Jul 29, 2026$1.71$1.81$1.695$1.7326.76K
Jul 28, 2026$1.68$1.79$1.59$1.7446.46K
Jul 27, 2026$1.72$1.7745$1.57$1.7519.18K
Jul 24, 2026$1.71$1.77$1.66$1.7653K
Jul 23, 2026$1.67$1.86$1.6505$1.7154.16K
Jul 22, 2026$1.87$1.94$1.70$1.7657.85K
Jul 21, 2026$1.77$2.00$1.77$1.93139.1K

Latest XCUR news

The latest Smart Investors Daily articles mentioning XCUR.

Stock researchCompany · Overview

XCUR research

Overview

Company profile and research snapshot.

Company profile

Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$12.00
Implied upside
—
Analysts
6
XCUR recent ratings
DateFirmRatingTarget
Aug 16, 2022Chardan CapitalNeutral—
Dec 13, 2021Chardan CapitalNeutral—
Nov 23, 2021Chardan CapitalBuy—
May 17, 2021HC Wainwright & Co.Buy—
Dec 18, 2020BMO CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 3, 2026

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement. The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including th

Yahoo · Jun 30, 2026

Exicure Announces Board and Committee Changes

WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions approved by the Company's Board of Directors at its special meeting held on June 24, 2026. The Company's Board of Directors accepted the resignation of Jung Kyu Ham as a director, effective June 30, 2026. The Board also appointed Jin Young Go as a Class III director to fill the vacancy created by Mr.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By